Champions Oncology Stock Discussion

$Champions Oncology (CSBR.US)$
Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million
Positive
▪️Revenue increased 12% year-over-year to $14.1 million
▪️Margin improved to 50% from 38.8% in the previous year
▪️Achieved adjusted EBITDA of $2.0 million, compared to a loss of $1.7 million last year
▪️Reported net income of $1.3 million
▪️Total costs and operating expenses decreased by $2.4 million or 15.8%
▪️Cost of oncology services decreased by 8.0%
▪️...

$Champions Oncology (CSBR.US)$ First Quarter Highlights:
Total revenue increased 12% to $14.1 million
Margin improved to 50%
Adjusted EBITDA of $2.0 million
Net income of $1.3 million
EPS 0.01 a 94%+ increase

$Champions Oncology (CSBR.US)$ is on the downward trend for a bit

$Champions Oncology (CSBR.US)$
Champions Oncology Reports Quarterly Revenue of $14.0 Million
Champions Oncology (Nasdaq: CSBR) reported its financial results for Q4 and fiscal year 2024.
Q4 revenue increased 7% to $14 million, with an adjusted EBITDA income of $884,000.
However, annual revenue decreased 7% to $50.2 million, with a fiscal year 2024 adjusted EBITDA loss of $3.9 million.
The company faced challenges due to the biotech sector's funding environment and pharmaceutical spending p...

$Champions Oncology (CSBR.US)$
Champions Oncology and Medicines Discovery Catapult Forge Partnership to Accelerate Radiopharmaceutical Therapeutics Development
Champions Oncology (CSBR) announced a strategic collaboration with Medicines Discovery Catapult (MDC) to boost the development of radiopharmaceutical therapeutics. This partnership leverages Champions' patient-derived models and pharmacology solutions with MDC's radiochemistry and multi-modal imaging expertise. The collaboration aims...

$Champions Oncology (CSBR.US)$ a value orented company. Consistant growth for years.